Two weeks after Trump unveiled plan to lower drug prices, two cancer drugs got a $1000-per-month price hike - (The Washington Post via NewsPoints Desk)

  • An analysis revealed that the prices of several drugs were raised after US President Donald Trump unveiled a blueprint targeting drug pricing, Washington Post reported Friday.

  • Wells Fargo analyst David Maris noted that while fewer price hikes occurred in May, there were double-digit price increases on several older drugs, while Bayer raised the prices of the cancer drugs Nexavar and Stivarga by 8 percent.

  • "That is an exceptionally bold move to increase prices by over $1000 a month on an already expensive set of cancer treatments, given the political context," remarked Stacie Dusetzina, associate professor of cancer research at Vanderbilt University Medical Center.

  • The news comes after Trump also predicted that drugmakers will be announcing major price reductions in the coming weeks.

  • "As we manage our current portfolio, we have to balance current operations, ensure broad access to novel medicines for patients, and continue development of more life-saving and life-changing medicines," explained Bayer spokesman Christopher Loder, continuing "on addition, Bayer offers numerous programs for patients who cannot afford their medicines."

  • Regarding larger pricing trends, Johnson & Johnson, Merck & Co. and Sanofi all said their net prices fell last year, while Eli Lilly posted a 6-percent increase in net prices.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>    

To read more NewsPoints articles, click here.